This is why I think Africans test HIV+, just so you know

''Human T-cell lymphotropic virus type III (HTLV-III) can be grown on the leukemic
cell line H9 and prepared for HTLV-III antibody testing by enzyme-linked
immunosorbent assay (ELISA). 2 kits licensed by the US Food and Drug
Administration are now available for screening of blood donors and high-risk groups.
We have tested HLA antisera in the Abbott ELISA (batches 74089 HR and 75207
HR). 152 HLA-A, B, C antisera (commercially available or obtained via exchange
programs) were clearly negative. However, of 310 HLA-DR antisera 10 gave positive
HTLV-III antibody results. The HTLV-III antibody ELISA from Electro-Nucleonics
Inc (fistributed by Viramed, Munich), master lot 2362, HTLV-III plate lot 4301018,
also gave positive results with all of the above HLA-DR4 antisera except for 9w594.
These data suggest that DR4 is present on the H9 cell and also as a contaminant on
the HTLV-III antigen coated beads used for ELISA test. The fact that no other DR
specificity was detected besides DR4 may indicate DR4 homozygosity or
heterozygosity for DR4 and an unknown 2nd DR antigen or loss of the 2nd DR
antigen on the infected leukemic H9 cell line. Cross-absorption studies with DR4-
positive B-cell suspensions revomed the DR4 antibodies from Biotest 512731 and
Frsenius 7297 (loss of reactivity against DR4-positive B cells in the 2-color-
fluorescence technique); a subsequent HTLV-III test on the absorbed sera became
clearly negative. A direct absorption of DR4 antisera on the antigen-coated test beads
for further tests of DR4 reactivity was impossible because of the necessary 1:440
predilution of the sera in the standard ELISA procedure. Since an antigenic relation
between HLA-DR4 and HTLV-III or the probability that all 9 donors of the different
DR4 antisera were HTLV-III infected is unlikely, the recognition of DR4 antibodies
in the sera of homosexuals (immunized by sperm and white blood cells),
hemophiliacs, and patients on hemodialysis is important in the interpretation of
positive HTLV-III antibody ELISA results.''
http://www.popline.org/node/419819#sthash.oZ3ebl17.dpuf

In South Africa they have a rate of around 18% of pre-eclampsia, which also features
HLA-DR4.
Pre-eclampsia is associated with HLA-DR4 sharing between mother and fetus
http://www.ncbi.nlm.nih.gov/pubmed/2371715?dopt=Abstract

Association between susceptibility to pre-eclampsia within families and HLA DR4.

http://www.ncbi.nlm.nih.gov/pubmed/2572795

And all Africans with autoimmune diseases like arthritis and psoriasis will also
appear 'HIV' positive because of their HLA-DR4 genes.

"There was a significant association of HLA-DR4 with Rheumatoid Arthritis. The

frequency of DR4 in RA was 44% in comparison with 10% in controls'
HLA associations with rheumatoid arthritis in African blacks.
http://www.ncbi.nlm.nih.gov/pubmed/2810257
All of those studies were in the late 80's but it's clear that HIV antibody tests cross
react with activated HLA-DR genes in pre-eclampsia, cancers and all autoimmune
diseases and should be taken off the market immediately despite long standing beliefs
that the HIV antibody is a diagnostic test for a virus.

"During preliminary experiments to establish the proportion of virus-coded p24

protein to virus membrane-associated HLA-DR in gradient-enriched HIV-1
preparations, we became aware of a large variability between experiments. In order to
determine whether HLA-DR-containing cellular material was contaminating the virus
preparations, we carried out enrichment by gradient centrifugation of clarified
supernatants from noninfected cells and tested this material for HLA-DR content. We
found that, independently of the cell type used, gradient enrichment resulted in the
isolation of large quantities of HLA-DR-containing material which banded at a
density overlapping that of infectious HIV." Cell Membrane Vesicles Are a Major
Contaminant of Gradient-Enriched Human Immunodeficiency Virus Type-1
Preparations http://www.sciencedirect.com/science/article/pii/S0042682297984531

Retroviruses in Human Lymphoma/Leukemia 1985

So called HIV tests have always been about Lymphoma and tumour cell detection.

This is Gallo's study in February of 1984 about finding p24 in cancer patients. In their
own words they were about to commercialise the p24 antigen test as a measure of
how big a tumour was. But any detection of retroviruses in tumours is irrelevant as
they are full of retroviruses anyway as was found out later in research from this
century.
"Circulating immune complexes from two patients with human T-cell leukaemia/
lymphoma virus (HTLV)-related lymphoma were shown to contain the major internal
antigen of the virus, p24.
The amount of complex-bound p24 in sequential serum samples correlated roughly
with tumour cell mass.
Small amounts of complex-bound p24 were detected in samples before a relapse
became clinically manifest.
Measurement of complex-bound p24 in patients with HTLV-associated lymphomas
and leukaemias might thus be helpful in management of malignancies and offer the
possibility of detecting imminent relapse and preventing it by intensification of
treatment."
DEMONSTRATION OF VIRAL ANTIGEN p24 IN CIRCULATING IMMUNE
COMPLEXES OF TWO PATIENTS WITH HUMAN T-CELL
LEUKAEMIA/LYMPHOMA VIRUS (HTLV) POSITIVE LYMPHOMA ...Feb 1984
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2884%2990358-
1/abstract
So within 2 months you have to ask how did a p24 antigen to detect tumour size
suddenly become a deadly sex virus in gays and this was all claimed as the cause of
AIDS at a press conference without any reference to other researchers.
When those gays involved had cancers from popper use and other party drugs
anyway.

"The amount of complex-bound p24 in sequential serum samples correlated

roughly with tumour cell mass." This above means the size of a tumour can affect
the HIV test measure levels...
"Small amounts of complex-bound p24 were detected in samples before a
relapse became clinically manifest." means they found p24 was a measure of a
tumour coming back before it was found
"Measurement of complex-bound p24 in patients with HTLV-associated
lymphomas and leukaemias might thus be helpful in management of
malignancies..." means they were about to commercialise the p24 test as a measure
for detecting tumours before they appeared.

Not a sexually transmitted deadly immune damaging virus as claimed two months
later at a press conference.

My opinion on the subject.

Cal Crilly